{
    "name": "burosumab",
    "comment": "Rx",
    "other_names": [
        "Crysvita",
        "burosumab-twza"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Endocrine"
    ],
    "source": "https://reference.medscape.com/drug/crysvita-burosumab-1000250",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to inform a drug-associated risk of adverse developmental outcomes",
            "In utero, burosumab exposure in cynomolgus monkeys did not result in teratogenic effects; adverse effects (eg, late fetal loss, preterm birth) observed in pregnant cynomolgus monkeys; however, these effects are unlikely to indicate clinical risk because they occurred at a drug exposure that was 64-fold higher, by AUC, than the human exposure at 1 mg/kg q4Weeks and were accompanied in the non-XLH monkeys by maternal hyperphosphatemia and placental mineralization",
            "Report pregnancies to the Ultragenyx Adverse Event reporting line at 1-888-756-8657"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information regarding the presence of burosumab in human milk or the effects on milk production or the breastfed infant",
            "Maternal IgG is present in breast milk; however, the effects of local GI exposure and limited systemic exposure to burosumab in the breastfed infant are unknown",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for burosumab and any potential adverse effects on the breastfed infant from burosumab or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Coadministration with oral phosphate and active vitamin D analogs",
                "Serum phosphorus within or above the reference range for age",
                "Severe renal impairment or end-stage renal disease (these conditions associated with abnormal mineral metabolism)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, rash, urticaria) reported; discontinue if serious hypersensitivity reactions occur and initiate appropriate medical treatment",
                "Increases in serum phosphorus to >ULN may be associated with increased risk of nephrocalcinosis; for patients already taking burosumab and with tumor-induced osteomalacia who undergo treatment of underlying tumor should have dose interrupted or reduced based on serum phosphorus levels to prevent hyperphosphatemia",
                "Local injection site reactions may occur; discontinue if severe injection site reactions occur and administer appropriate medical treatment"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "8-73"
        },
        {
            "name": "Injection site reaction",
            "percent": "23-67"
        },
        {
            "name": "Vomiting",
            "percent": "46-48"
        },
        {
            "name": "Pyrexia",
            "percent": "44-62"
        },
        {
            "name": "Pain in extremity",
            "percent": "23-46"
        },
        {
            "name": "Vitamin D decreased",
            "percent": "15-37"
        },
        {
            "name": "Rash",
            "percent": "8-27"
        },
        {
            "name": "Toothache",
            "percent": "15-23"
        },
        {
            "name": "Hypersensitivity",
            "percent": "22"
        },
        {
            "name": "Myalgia",
            "percent": "8-17"
        },
        {
            "name": "Tooth abscess",
            "percent": "15-23"
        },
        {
            "name": "Dizziness",
            "percent": "15"
        },
        {
            "name": "Back pain",
            "percent": "15"
        },
        {
            "name": "Headache",
            "percent": "13"
        },
        {
            "name": "Tooth infection",
            "percent": "13"
        },
        {
            "name": "Restless legs syndrome",
            "percent": "12"
        },
        {
            "name": "Vitamin D decreased",
            "percent": "12"
        },
        {
            "name": "Injection site rash",
            "percent": "6"
        },
        {
            "name": "Urticaria",
            "percent": "5"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "Constipation",
            "percent": "9"
        },
        {
            "name": "Blood phosphorus increased",
            "percent": "6"
        }
    ]
}